| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥7153.9B | ¥7252.2B | -1.4% |
| Operating Income | ¥702.5B | ¥1088.0B | -35.4% |
| Profit Before Tax | ¥669.2B | ¥1052.2B | -36.4% |
| Net Income | ¥433.6B | ¥763.8B | -43.2% |
| ROE | 5.6% | 10.2% | - |
FY2026 Q3 cumulative results: Revenue 715.4B yen (YoY -1.4%), Operating Income 70.3B yen (-35.4%), Ordinary Income 66.9B yen (-36.4%), Net Income 43.4B yen (-43.2%). Revenue remained essentially flat while profitability deteriorated significantly across all profit levels. The decline was driven by increased SG&A expenses following segment reorganization and cost allocation changes, equity method losses of -3.7B yen (compared to +0.2B yen prior year), and impairment charges of 3.6B yen. Operating margin compressed 5.2 percentage points from 15.0% to 9.8%, reflecting substantial operational headwinds despite maintaining a high gross margin of 64.5%.
Revenue declined 1.4% YoY to 715.4B yen, with Gastrointestinal Solutions segment recording 487.2B yen (-1.3% YoY) and Surgical and Interventional Solutions at 228.0B yen (-1.5% YoY). The company implemented organizational restructuring on April 1, 2025, reorganizing from "Endoscopy" and "Therapeutic Devices" segments into "Gastrointestinal Solutions" and "Surgical Intervention" segments, accompanied by revisions to common cost allocation methodology. This structural change impacts year-over-year comparability.
On the profit side, gross profit margin remained robust at 64.5% (46.1B yen decrease in absolute terms), but operating income contracted sharply by 35.4% to 70.3B yen. SG&A expenses increased 4.8B yen (+1.3%) to 367.7B yen despite flat revenue, with the SG&A ratio rising from 50.1% to 51.4%. The deterioration was compounded by equity method losses shifting from +0.2B yen to -3.7B yen, primarily driven by a -4.4B yen loss in the Gastrointestinal Solutions segment. Other expenses increased 4.4B yen to 28.4B yen, including impairment charges of 3.6B yen (vs. 2.5B yen prior year), with 3.5B yen recognized in the Surgical and Interventional Solutions segment.
Non-operating items further pressured net income. Finance income increased to 5.4B yen from 2.7B yen, but finance costs rose to 8.8B yen from 6.3B yen, resulting in net financial expenses of 3.3B yen. The gap between operating income (70.3B yen) and ordinary income (66.9B yen) reflects this 3.3B yen net financial burden. Tax expense of 23.6B yen on profit before tax of 66.9B yen implies an effective tax rate of 35.2%. The substantial gap between operating income (-35.4% YoY) and net income (-43.2% YoY) stems from the combined impact of deteriorating non-operating performance and sustained tax burden.
This represents a "revenue flat/profit down" pattern, driven by structural cost increases from organizational changes, segment-specific impairments, and unfavorable non-operating dynamics.
Gastrointestinal Solutions generated revenue of 487.2B yen (-1.3% YoY) with operating income of 95.1B yen (-18.4% YoY), representing the company's core business with approximately 68% of total revenue. Operating margin for this segment was 19.5% (calculated), down from 23.6% in the prior year. The segment experienced equity method losses of -4.4B yen compared to -0.02B yen prior year, indicating deterioration in associated company performance.
Surgical and Interventional Solutions recorded revenue of 228.0B yen (-1.5% YoY) with an operating loss of -10.6B yen (compared to operating income of 7.3B yen prior year), reflecting a significant profitability reversal. The segment incurred impairment charges of 3.5B yen and faced operational challenges. Operating margin turned negative at -4.6% from +3.1% prior year.
The Other segment (new business R&D and exploration activities) contributed minimal revenue of 0.2B yen with operating loss of -0.06B yen. Corporate/unallocated adjustments totaled -14.2B yen in operating expenses, consistent with prior year's -14.6B yen, including 6.0B yen income from licensing agreements with Evidant Corporation.
The significant margin differential between segments (19.5% vs. -4.6%) highlights the concentration of profitability in Gastrointestinal Solutions, while Surgical and Interventional Solutions faces restructuring challenges requiring management attention.
[Profitability] ROE 5.6% declined from prior year levels, reflecting compressed net profit margins. Operating margin of 9.8% represents a 5.2 percentage point contraction from 15.0% YoY, indicating substantial operational leverage deterioration. Net profit margin compressed to 6.1% from 10.5% YoY. The DuPont 3-factor decomposition shows ROE of 5.6% driven by net profit margin 6.1%, asset turnover 0.491, and financial leverage 1.89x. [Cash Quality] Cash and equivalents of 169.5B yen provide adequate liquidity coverage. Operating cash flow of 59.3B yen represents 1.37x net income, confirming cash-backed earnings quality. However, working capital efficiency deteriorated with inventories increasing 27.8B yen to 214.9B yen. [Investment Efficiency] Total asset turnover of 0.491 falls below the industry median of 0.56, indicating room for improvement in asset utilization. ROIC calculated at approximately 4.8% (operating income 70.3B yen / invested capital) reflects the impact of margin compression. [Financial Health] Equity ratio of 53.0% remains healthy and consistent with prior period 52.4%. Total assets increased 2.5B yen to 1,457.9B yen. Net debt position (borrowings 238.0B yen minus cash 169.5B yen = 68.5B yen net debt) represents modest leverage. Interest-bearing debt totaled 238.0B yen (78.2B yen current, 159.6B yen non-current), manageable against equity of 773.3B yen.
Operating CF of 59.3B yen represents 1.37x net income, confirming earnings quality with cash generation exceeding accounting profits. The operating CF before working capital changes was 117.0B yen, but working capital movements consumed cash: inventory increase of 18.8B yen and income taxes paid of 56.4B yen were significant outflows. Investing CF of -67.7B yen comprised primarily CapEx of 44.4B yen and intangible asset acquisitions. Financing CF of -82.3B yen reflected dividends of 22.6B yen and substantial share buybacks of 50.0B yen. FCF of -8.4B yen (operating CF 59.3B yen + investing CF -67.7B yen) indicates that operational cash generation was insufficient to cover investment activities. The cash position decreased from 252.5B yen to 169.5B yen (-83.0B yen), primarily due to aggressive capital allocation toward shareholder returns totaling 72.6B yen (dividends + buybacks) while maintaining investment spending. The CapEx/D&A ratio of 0.88 (44.4B yen / 50.7B yen) suggests maintenance-level investment, though combined with intangible asset acquisitions the total investment intensity remains significant. FX effects contributed positively at 7.7B yen. The negative FCF combined with substantial shareholder returns raises questions about capital allocation sustainability if operational performance does not improve.
Operating income of 70.3B yen versus ordinary income of 66.9B yen shows a net non-operating burden of approximately 3.3B yen. This comprises finance income of 5.4B yen offset by finance costs of 8.8B yen, plus equity method losses of 3.7B yen. Non-operating expenses represent 4.6% of revenue and include other expenses of 28.4B yen (including 3.6B yen impairment charges) partially offset by other income of 8.7B yen. The 6.0B yen income from licensing agreements with Evidant Corporation represents a potentially non-recurring item that benefited results. Operating CF of 59.3B yen exceeds net income of 43.4B yen by 1.37x, indicating healthy cash conversion despite profit margin compression. However, the CF/NI ratio declined from higher prior period levels (prior year operating CF was 126.2B yen versus net income of 76.4B yen = 1.65x), suggesting some deterioration in working capital efficiency. The working capital metrics show concerning trends: inventory days increased substantially and accounts receivable collection patterns suggest operational stress. Core operating earnings quality appears solid given the cash conversion ratio, but the substantial non-operating losses, impairment charges, and one-time licensing income warrant adjustment when assessing normalized earning power. The effective tax rate of 35.2% is elevated and should be monitored for sustainability.
Full-year revenue guidance of 998.0B yen (+0.1% YoY) implies Q4 revenue of 282.6B yen. Q3 cumulative revenue of 715.4B yen represents 71.7% progress against the full-year target, indicating slightly slower-than-proportional achievement (standard Q3 expectation: 75%). The 2.8 percentage point shortfall suggests potential conservatism in initial guidance or anticipated Q4 recovery. The company revised its full-year forecast during the current quarter, though specific changes to profit targets were not disclosed in the provided data. Based on Q3 cumulative operating income of 70.3B yen at 9.8% margin, implied Q4 would require significant margin expansion to achieve full-year targets if operating profit guidance was maintained. The annual dividend forecast of 30.00 yen remains unchanged with no revision this quarter, implying management confidence in full-year cash generation despite operating headwinds. Progress rate divergence and forecast revision indicate cautious outlook management amid operational challenges from segment reorganization and cost structure adjustments.
Annual dividend forecast of 30.00 yen consists of interim dividend already paid and year-end dividend of 20.00 yen (Q2 showed zero interim dividend, suggesting the 30.00 yen is entirely year-end). Based on full-year diluted EPS guidance and current net income run rate, the payout ratio calculates to approximately 51.4% against Q3 cumulative annualized earnings. Share buybacks during the nine-month period totaled 50.0B yen, representing substantial capital return. Combined with dividends paid of 22.6B yen, total shareholder returns amounted to 72.6B yen. The total return ratio (dividends + buybacks relative to net income) calculates to approximately 167% on a cumulative basis, exceeding net income and FCF generation. This aggressive capital allocation is supported by the 169.5B yen cash position and 59.3B yen operating CF, though the sustainability of this return level depends on operational recovery. The 50.0B yen buyback represents approximately 4.5% of current market capitalization and demonstrates management's commitment to shareholder returns despite near-term earnings pressure. No dividend revision was announced this quarter, signaling confidence in maintaining the 30.00 yen annual dividend policy.
Working capital efficiency deterioration with inventory days of 309 and receivables days of 100 creates cash cycle of 328 days, substantially elevated compared to efficient peers and indicating potential demand softness, supply chain overcorrection, or collection challenges. The 27.8B yen inventory increase (+14.9%) against flat revenue represents approximately 3.9% of revenue tied up in excess stock, risking obsolescence and requiring management focus.
Segment reorganization and cost allocation changes implemented April 1, 2025 impair year-over-year comparability and may obscure underlying business trends. The shift in common cost allocation methodology and the -10.6B yen operating loss in Surgical and Interventional Solutions (from +7.3B yen profit prior year) raises questions about both allocation impacts and genuine operational deterioration requiring detailed management explanation.
Capital allocation sustainability concerns arise from total shareholder returns of 72.6B yen exceeding both net income of 43.4B yen and negative FCF of -8.4B yen. Maintaining 50.0B yen annual buyback pace alongside 22.6B yen dividends requires either operational improvement or drawdown of cash reserves (already declined 83.0B yen to 169.5B yen), with current cash providing approximately 2.3 years of coverage at present return levels but constraining strategic flexibility.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE 5.6% aligns with industry median of 5.8% (2025-Q3, n=105), indicating average profitability performance despite recent deterioration. Operating margin of 9.8% exceeds industry median of 8.9%, though this represents a decline from the company's prior 15.0% level. Net profit margin of 6.1% falls slightly below industry median of 6.5%.
Financial Health: Equity ratio of 53.0% is below industry median of 63.8%, suggesting moderately higher leverage utilization while remaining within healthy parameters. Current ratio data not disclosed but cash position of 169.5B yen against short-term borrowings of 78.2B yen indicates adequate liquidity coverage of 2.2x for debt obligations.
Efficiency: Asset turnover of 0.491 underperforms industry median of 0.56, indicating suboptimal asset utilization and opportunity for improvement. Operating working capital turnover of 328 days (calculated from inventory, receivables, and payables data) significantly exceeds industry median of 111.50 days, representing a material efficiency gap. Inventory turnover of 309 days substantially exceeds industry median of 112 days, confirming excess inventory as a critical issue.
Growth: Revenue decline of -1.4% compares unfavorably to industry median growth of +2.8%, positioning the company in the lower quartile for top-line expansion. EPS decline of -41.5% falls well below industry median EPS growth of +9%, reflecting the company's significant earnings pressure.
※ Industry: Manufacturing (105 companies), Comparison: 2025-Q3 period, Source: Proprietary analysis
Significant operational inflection point observed with operating margin compression of 5.2 percentage points from 15.0% to 9.8%, driven by segment reorganization, cost allocation changes, and segment-specific challenges in Surgical and Interventional Solutions (operating profit swung from +7.3B yen to -10.6B yen). The structural nature of these changes requires monitoring over subsequent quarters to distinguish reorganization-related temporary impacts from fundamental business deterioration.
Working capital efficiency deterioration represents a quantifiable near-term improvement opportunity, with inventory days of 309 and cash conversion cycle of 328 days both substantially exceeding industry medians and historical norms. The 27.8B yen inventory increase against flat revenue suggests potential for 20-30B yen cash release through inventory optimization, which would restore FCF to positive territory and support the current dividend policy more sustainably.
Capital allocation strategy demonstrates strong shareholder orientation with total returns of 72.6B yen (167% of net income) comprising 50.0B yen buybacks and 22.6B yen dividends, though sustainability depends on operational recovery given negative FCF of -8.4B yen and declining cash position (from 252.5B yen to 169.5B yen). The 30.00 yen annual dividend at 51.4% payout ratio appears maintainable from operating CF of 59.3B yen, but continuation of 50.0B yen annual buyback pace without operational improvement would constrain financial flexibility within 2-3 years.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.